Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

CGS-35066: potent and specific ECE inhibitor presented at ET-6

Nov. 2, 1999

New type III antiarrhythmic marketed in Japan

Nov. 2, 1999

AGI-1067 and related AtheroGenics compounds licensed to Schering-Plough

Oct. 29, 1999

ETA/ETB antagonist tezosentan is a promising parenteral treatment for acute conditions

Oct. 29, 1999

Scios begins patient enrollment in phase III Natrecor trial

Oct. 28, 1999

Ion channel-blocking antiarrhythmic and anesthetic agents from Nortran

Oct. 28, 1999

Increasing NO levels in blood as novel strategy for sickle cell disease

Oct. 21, 1999

Texas Biotechnology announces new preclinical, clinical data and future plans for sitaxsentan

Oct. 19, 1999

Teveten now available in the U.S.

Oct. 19, 1999

Texas Biotechnology presents new ETA antagonists at ET-6

Oct. 19, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...